This post details the Maekyung Report, which came out late yesterday, on MBK's potential tender offer to Osstem Implant shareholders at a 20% premium for a 15% stake.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.